This study found that patients deemed as intermediate metabolizers as determined by CYP2D6 enzyme activity had a higher risk of vivax malaria recurrence than did those deemed as normal or ultrarapid metabolizers. This evidence concerns the gene CYP2D6 and Plasmodium vivax malaria.